August 22, 2012
1 min read
Save

Photoreceptor integrity may help predict treatment response in AMD patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Visual acuity in eyes with age-related macular degeneration may be predicted with the status of photoreceptor integrity, according to a study.

The retrospective review analyzed 87 eyes of 84 patients with neovascular AMD who were treated with anti-VEGF injections.

All patients received three consecutive monthly anti-VEGF injections, followed by as-needed dosing. Spectral domain optical coherence tomography (SD-OCT) images were taken at baseline and at 1 and 2 months after the three monthly injections.

The status of the inner segment/outer segment (IS/OS) photoreceptor junction was classified into three groups. The IS/OS+ group had a nearly intact IS/OS line and disruptions less than 200 µm. The IS/OS± group had disruptions between 200 µm and 800 µm. The IS/OS– group had disruptions greater than 800 µm.

Patients were redistributed among the three groups based on the SD-OCT images taken at the three time intervals.

Between baseline and 1 month, a significant difference existed in the ratio of the IS/OS+ group (P < .001). Better visual acuity and an improvement of the IS/OS line was seen in 43 eyes from baseline to 1 month (P < .016).

Although better visual acuity was significantly correlated to the status of the IS/OS line at 1 month and 2 months, better visual acuity at follow-up did not correlate to the status of the IS/OS line at baseline.

No significant difference existed in the IS/OS line between 1 month and 2 months. No further improvement was detected at 2 months.

“Assessing the change of the photoreceptor integrity before and after treatment would be a useful indicator to predict initial response to treatment and visual prognosis in patients with neovascular AMD,” the study authors said.